Healthcare
Masimo Corporation(MASI)
Live Price
Offline$179.95
+0.00% today
1Y Change
+7.94%
Window
Jun 26, 2025 โ Jun 12, 2026
- Market Cap
- $9.35B
- Revenue Growth
- -27.1%
- EPS Growth
- +50.5%
- Dividend Yield
- 0.0%
Coverage: 242 bars ยท Jun 26, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Masimo Corporation (MASI) is a Healthcare stock with a market cap of $9.35B and listed on NASDAQ. The stock last traded around $179.95 and up 7.9% across the available one-year price window (Jun 26, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of -27.1%, EPS growth of +50.5%, a dividend yield of 0.0%. What stands out right now is revenue -27.1%, EPS +50.5%, free cash flow +36.1% with operating margin 20.3% and ROIC 17.6%. Valuation sits in the middle of the pack at price/sales 6.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MASI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-27.1% vs +7.6% peer median
Operating Margin
Near sector median
+20.3% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -27.1% and EPS is at +50.5%, with operating margin around 20.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | -0.1% | -0.0% | +0.1% |
2026 Feb 26, 2026 | -87.8% | +0.1% | +0.1% | +1.0% |
2025 Nov 4, 2025 | +10.9% | -4.6% | -1.6% | -7.3% |
Benchmark Edge
MASI vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MASI
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MASI Max Drawdown
-25.64%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MASI and SPY.
Company Overview
Masimo Corporation
NASDAQ Global Select
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.
- Leadership
- Catherine Szyman
- IPO Date
- Aug 8, 2007
- Employees
- 3.6k
- Street Address
- 52 Discovery
- Mailing
- Irvine, CA, 92618
- Region
- Irvine, CA, US
- Reporting Currency
- USD
- Investor Line
- 949 297 7000
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 28.3
- Price/Sales
- 6.1
- Price/Book
- 13.3
Growth
- Revenue
- -27.1%
- EPS
- +50.5%
- Free Cash Flow
- +36.1%
Profitability
- Gross Margin
- 61.9%
- Operating Margin
- 20.3%
- Net Margin
- -9.9%
- ROE
- -17.2%
- ROIC
- 17.6%
Balance Sheet
- Debt/Equity
- 0.78
- Current Ratio
- 2.49
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.